Emilio Esteban

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh et al. · The Lancet Oncology · 2010 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 744 citations

Medicine, Oncology, Pharmacology +16

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina Chiara Garassino, Shirish M. Gadgeel, Giovanna Speranza et al. · Journal of Clinical Oncology · 2023 · 643 citations · Full text

Medicine, Oncology, Pharmacotherapy +16